1 ial infarction, according to progestin type: norethindrone, 2.2 (1.5 to 3.2) and 2.3 (1.3 to 3.9); le

2                                              Norethindrone acetate (NETA), another progestin used in

3  relugolix, 1 mg of estradiol, and 0.5 mg of norethindrone acetate), or delayed relugolix combination

4 hormones; in this case, estradiol, 1 mg, and norethindrone acetate, 0.5 mg, once daily) in women with

5 hormone-receptor antagonist), estradiol, and norethindrone acetate, administered once daily, may have

6 indole units with clinically used drugs like norethindrone and danazol.

7 ition, other potent steroid agonists such as norethindrone and mometasone furoate have larger substit

8 stigens, norethynodrel, cyproterone acetate, norethindrone, and megestrol acetate, were found to be o

9 thinyl estradiol at a dose of 35 microg plus norethindrone at a dose of 0.5 to 1 mg for 12 cycles of

10  in the metribolone complex to 520 A3 in the norethindrone complex, 565 A3 in the progesterone comple

11 progestogens (principally levonorgestrel and norethindrone) continues.

12 raceptive agents, progesterone, desogestrel, norethindrone, megestrol, algestone, norprogesterones, a

13 ogestins (medroxyprogesterone acetate (MPA), norethindrone (NET), and levonorgestrel (LNG)) used by w

14 es induced by 2, 20, and 200 ng/L P4, RU486, norethindrone (NET), and levonorgestrel (LNG).

15 rogestins used in oral contraceptives (e.g., norethindrone, norgestrel, and norethynodrel), hormone r

16 iphasic dosing with an average of 0.75 mg of norethindrone (OR, 3.1; 95% CI, 1.9-5.1; Pheterogeneity

17 lofenac, gemfibrozil, ibuprofen, ketoprofen, norethindrone, propranolol, and warfarin) with differing